Nuveen LLC Purchases Shares of 78,145 Candel Therapeutics, Inc. $CADL

Key Points

• Nuveen LLC has acquired 78,145 shares of Candel Therapeutics, valued at approximately $442,000, increasing its stake to 0.16% in the company.
• Candel Therapeutics recently reported earnings of ($0.09) EPS, surpassing the consensus estimate of ($0.17), and the stock has a target price consensus of $20.00.
• Several institutional investors increased their holdings in Candel Therapeutics, with Charles Schwab Investment Management Inc. significantly raising its stake by 60.7% during the first quarter.

Nuveen LLC bought a new stake in shares of Candel Therapeutics, Inc. (NASDAQ:CADL - Free Report) in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 78,145 shares of the company's stock, valued at approximately $442,000. Nuveen LLC owned 0.16% of Candel Therapeutics as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently modified their holdings of CADL. Halter Ferguson Financial Inc. raised its stake in Candel Therapeutics by 1.7% in the first quarter. Halter Ferguson Financial Inc. now owns 693,153 shares of the company's stock valued at $3,916,000 after purchasing an additional 11,819 shares in the last quarter. Northern Trust Corp raised its position in shares of Candel Therapeutics by 3.9% in the 4th quarter. Northern Trust Corp now owns 165,021 shares of the company's stock valued at $1,432,000 after buying an additional 6,250 shares in the last quarter. HB Wealth Management LLC lifted its holdings in shares of Candel Therapeutics by 8.0% during the 1st quarter. HB Wealth Management LLC now owns 94,300 shares of the company's stock worth $533,000 after acquiring an additional 7,000 shares during the period. Charles Schwab Investment Management Inc. boosted its position in shares of Candel Therapeutics by 60.7% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 83,880 shares of the company's stock worth $474,000 after acquiring an additional 31,690 shares in the last quarter. Finally, Nuveen Asset Management LLC increased its stake in Candel Therapeutics by 3.0% in the fourth quarter. Nuveen Asset Management LLC now owns 68,226 shares of the company's stock valued at $592,000 after acquiring an additional 2,009 shares during the last quarter. Institutional investors own 13.93% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on CADL shares. Brookline Capital Management upgraded Candel Therapeutics to a "strong-buy" rating in a research note on Wednesday, July 9th. HC Wainwright upgraded Candel Therapeutics to a "buy" rating and set a $23.00 price objective for the company in a research report on Monday, June 30th. Wall Street Zen lowered Candel Therapeutics from a "hold" rating to a "sell" rating in a research note on Friday, September 5th. Finally, Bank of America downgraded Candel Therapeutics from a "buy" rating to a "neutral" rating and lowered their target price for the stock from $13.00 to $7.00 in a research note on Wednesday, September 3rd. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Buy" and an average target price of $20.00.

Candel Therapeutics Trading Down 2.4%

Shares of NASDAQ:CADL traded down $0.12 during midday trading on Wednesday, hitting $4.85. 739,124 shares of the stock were exchanged, compared to its average volume of 727,173. The business's 50-day moving average price is $5.99 and its 200 day moving average price is $5.97. Candel Therapeutics, Inc. has a 12 month low of $3.79 and a 12 month high of $14.60. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.04 and a current ratio of 7.04. The stock has a market capitalization of $266.27 million, a price-to-earnings ratio of -7.03 and a beta of -0.90.

Candel Therapeutics (NASDAQ:CADL - Get Free Report) last posted its earnings results on Thursday, August 14th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.08. Analysts predict that Candel Therapeutics, Inc. will post -1.47 earnings per share for the current year.

About Candel Therapeutics

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.